E-viri
Recenzirano
Odprti dostop
-
Fischer-Valuck, Benjamin W.; Michalski, Jeff M.; Contreras, Jessika A.; Brenneman, Randall; Christodouleas, John P.; Abraham, Christopher D.; Kim, Eric H.; Arora, Vivek K.; Bullock, Arnold D.; Carmona, Ruben; Figenshau, Robert S.; Grubb, Robert; Knoche, Eric M.; Pachynski, Russell K.; Picus, Joel; Roth, Bruce J.; Sargos, Paul; Andriole, Gerald L.; Gay, Hiram A.; Baumann, Brian C.
Clinical and translational radiation oncology, 02/2019, Letnik: 15Journal Article
•Limited information is known about treatment outcomes for squamous cell carcinoma of the bladder (SqCC).•Treatment for SqCC is extrapolated from urothelial carcinoma.•Outcomes of chemoRT for SqCC are very limited.•Following chemoRT, patients with SqCC do worse than counterparts with urothelial carcinoma. Squamous cell carcinoma (SqCC) is the second most common histology of primary bladder cancer, but still very limited information is known about its treatment outcomes. Most bladder cancer trials have excluded SqCC, and the current treatment paradigm for localized SqCC is extrapolated from results in urothelial carcinoma (UC). In particular, there is limited data on the efficacy of definitive chemo-radiotherapy (CRT). In this study, we compare overall survival outcomes between SqCC and UC patients treated with definitive CRT. We queried the National Cancer Database (NCDB) for muscle-invasive (cT2-T4 N0 M0) bladder cancer patients diagnosed from 2004 to 2013 who underwent concurrent CRT. Propensity matching was performed to match patients with SqCC to those with UC. OS was analyzed using the Kaplan-Meier survival method, and the log-rank test and Cox regression were used for analyses. 3332 patients met inclusion criteria of which 79 (2.3%) had SqCC. 73.4% of SqCC patients had clinical T2 disease compared to 82.5% of UC patients. Unadjusted median OS for SqCC patients was 15.6 months (95% CI, 11.7–19.6) versus 29.1 months (95% CI, 27.5–30.7) for those with UC (P < 0.0001). On multivariable analysis, factors associated with worse OS included: SqCC histology HR: 1.53 (95% CI, 1.19–1.97); P = 0.001, increasing age HR: 1.02 (95% CI, 1.02–1.03); P < 0.0001, increasing clinical T-stage HR: 1.21 (95% CI, 1.13–1.29); P < 0.0001, and Charlson-Deyo comorbidity index HR: 1.26 (95% CI, 1.18–1.33); P < 0.0001. Seventy-seven SqCC patients were included in the propensity-matched analysis (154 total patients) with a median OS for SqCC patients of 15.1 months (95% CI, 11.1–18.9) vs. 30.4 months (95% CI, 19.4–41.4) for patients with UC (P = 0.013). This is the largest study to-date assessing survival outcomes for SqCC of the bladder treated with CRT. In this study, SqCC had worse overall survival compared to UC patients. Histology had a greater impact on survival than increasing T-stage, suggesting that histology should be an important factor when determining a patient’s treatment strategy and that treatment intensification in this subgroup may be warranted.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.